PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)

NCT06907784

Status	RECRUITING
Phase	Not Applicable
Sponsor	NHS Greater Glasgow and Clyde
Enrollment	2,000 participants

Key Eligibility Criteria

Inclusion (13)

- Capable of giving informed consent directly or via a legal representative (e.g., next of kin, welfare guardian, health care power of attorney).
- Participants who are newly prescribed one of the trial-eligible index drugs during their hospital stay may be approached for consent. Consent should be obtained within 3 days of the first dose of the index drug being administered. If there is a clear clinical plan documented on HEPMA indicating that the patient will be started on an eligible drug (but has not yet received the first dose), consent may be obtained in anticipation. However, formal trial enrolment will only occur once the first dose of the index drug has been administered.
- Participant must not have a prescription for this drug in the previous 3 months.
- Participant is able to provide a cheek swab
- Participant is able to take part and be followed-up for at least 12 weeks.

... and 8 more (see full listing online)

Exclusion (41)

- Inability to give informed consent directly or via a legal representative.
- Non-English speakers without translation support.
- Participants co-enrolled in other trials where a medication is one of the index drug is part of the trial protocol.
- Inability to give informed consent directly or via a legal representative.
- Non-English speakers without translation support.

... and 36 more (see full listing online)

Locations (1 total)

Queen Elizabeth University Hospital, Glasgow, United Kingdom